Morgan Stanley Maintains Equal-Weight on IGM Biosciences, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Lapides has maintained an Equal-Weight rating on IGM Biosciences (NASDAQ:IGMS) but lowered the price target from $20 to $15.
August 07, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on IGM Biosciences but lowered the price target from $20 to $15.
The lowering of the price target by Morgan Stanley from $20 to $15 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100